Hims & Hers Health (NYSE:HIMS) Shares Gap Down Following Analyst Downgrade

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) gapped down prior to trading on Monday after TD Cowen lowered their price target on the stock from $30.00 to $20.00. The stock had previously closed at $23.02, but opened at $17.83. TD Cowen currently has a hold rating on the stock. Hims & Hers Health shares last traded at $17.2790, with a volume of 40,482,980 shares trading hands.

HIMS has been the subject of several other reports. BTIG Research reduced their price target on Hims & Hers Health from $85.00 to $60.00 and set a “buy” rating for the company in a report on Monday, February 2nd. Zacks Research cut shares of Hims & Hers Health from a “hold” rating to a “strong sell” rating in a research note on Monday, January 19th. Bank of America dropped their price objective on Hims & Hers Health from $26.00 to $21.00 and set an “underperform” rating for the company in a research report on Monday. Wall Street Zen cut shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Finally, Barclays started coverage on Hims & Hers Health in a report on Monday, December 8th. They issued an “overweight” rating and a $48.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, nine have given a Hold rating and four have given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $39.32.

Insider Activity at Hims & Hers Health

In other news, insider Deborah M. Autor sold 7,054 shares of Hims & Hers Health stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total transaction of $258,952.34. Following the sale, the insider directly owned 6,175 shares of the company’s stock, valued at approximately $226,684.25. The trade was a 53.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Patrick Harrison Carroll sold 10,021 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total value of $367,870.91. Following the sale, the insider owned 169,940 shares in the company, valued at $6,238,497.40. This represents a 5.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 129,337 shares of company stock valued at $4,651,648. 17.71% of the stock is currently owned by insiders.

Hims & Hers Health News Summary

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers pulled its compounded oral semaglutide offering and said it has held “constructive conversations” with stakeholders — a quick damage‑control move that reduces near‑term regulatory exposure. Hims & Hers is scrapping plan for knockoff Wegovy weight-loss pill. Here’s why
• Positive Sentiment: Some analysts/commentators argue the market is overreacting because GLP‑1 weight‑loss was only a portion of revenue and the company’s broader telehealth platform remains intact. That view supports longer‑term recovery potential if legal/regulatory issues are contained. Hims & Hers Health: Don’t Fall For The Hysteria
• Neutral Sentiment: Some analysts and commentators say the company will survive but warn of a painful reset (“washout”) in the stock while management addresses regulatory/legal fallout. That implies more volatility ahead rather than binary insolvency risk. Hims & Hers Health: The Company Will Survive, But Investors Should Expect A ‘Washout’
• Negative Sentiment: Novo Nordisk filed a U.S. patent lawsuit seeking to block Hims & Hers’ compounded semaglutide products and recover damages — this escalates litigation risk and could lead to injunctions or material liability. Novo Nordisk opens new front with patent suit over Hims’ Wegovy copies
• Negative Sentiment: Multiple major outlets report Novo Nordisk’s broader legal offensive and threats that directly target Hims’ GLP‑1 initiative — raising the probability of costly, precedent‑setting litigation. Novo Nordisk sues Hims & Hers over cheaper copycat versions of Wegovy pill, injections
• Negative Sentiment: The FDA issued a warning letter related to Hims’ activities around compounded GLP‑1 products, which increases regulatory uncertainty and could prompt additional enforcement or restrictions. Hims & Hers’ Woes Compound as FDA Hits Company With Warning Letter
• Negative Sentiment: Analysts have trimmed price targets and ratings (Citigroup, TD Cowen, BofA among others) citing higher legal/regulatory risk and revenue uncertainty — a catalyst for further selling pressure. FDA Uncertainty Pushes Analyst To Lower Hims & Hers Forecast
• Negative Sentiment: Shareholder litigation/fraud investigations have been announced, potentially adding legal costs and management distraction. HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation
• Negative Sentiment: Market reaction: heavy volume, steep declines to multi‑month lows and elevated volatility reflect rapid de‑risking by investors; near‑term sentiment will track legal filings and any FDA follow‑ups. Hims & Hers stock poised for heavy losses after quick U-turn on plan for oral Wegovy competitor

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Farallon Capital Management LLC raised its position in shares of Hims & Hers Health by 30.8% during the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock valued at $609,561,000 after acquiring an additional 2,533,271 shares in the last quarter. Invesco Ltd. boosted its holdings in Hims & Hers Health by 502.2% in the second quarter. Invesco Ltd. now owns 2,552,405 shares of the company’s stock worth $127,237,000 after purchasing an additional 2,128,587 shares during the period. Norges Bank bought a new stake in Hims & Hers Health during the fourth quarter valued at $62,153,000. Clear Street LLC acquired a new stake in shares of Hims & Hers Health during the second quarter worth $83,582,000. Finally, Clear Street Group Inc. acquired a new stake in shares of Hims & Hers Health during the third quarter worth $87,372,000. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Stock Performance

The stock’s 50-day moving average price is $32.22 and its 200-day moving average price is $42.77. The company has a current ratio of 1.88, a quick ratio of 1.64 and a debt-to-equity ratio of 1.67. The company has a market capitalization of $3.92 billion, a P/E ratio of 31.93, a P/E/G ratio of 3.21 and a beta of 2.43.

Hims & Hers Health announced that its Board of Directors has authorized a share repurchase program on Monday, November 17th that authorizes the company to buyback $250.00 million in outstanding shares. This buyback authorization authorizes the company to purchase up to 3% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s management believes its shares are undervalued.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.